Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000032125
- Lead Sponsor
- Handa City Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) were excluded from this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Glycemic control is estimated as the mean blood glucose (MBG). Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE). Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L. Hyperglycemia, which is defined as a sensor value of >10.0mmol/L, was also calculated as a total time at >10.0mmol/L.
- Secondary Outcome Measures
Name Time Method